ERBB2 and neoplasm: Recently, Slaga and his colleagues have developed a modified 2 : 1 TCB (1Fab-IgG) with improvement of selectivity and potency against HER2-amplified tumor cells, while sparing cells that express low amounts of HER2 similar to normal human tissues (Figure 1(a), M) [54].